Sinphar Pharmaceutical Co Ltd (1734) - Net Assets
Based on the latest financial reports, Sinphar Pharmaceutical Co Ltd (1734) has net assets worth NT$3.72 Billion TWD (≈ $117.05 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$6.15 Billion ≈ $193.85 Million USD) and total liabilities (NT$2.44 Billion ≈ $76.81 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 1734 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$3.72 Billion |
| % of Total Assets | 60.38% |
| Annual Growth Rate | 6.49% |
| 5-Year Change | 20.73% |
| 10-Year Change | -1.77% |
| Growth Volatility | 12.1 |
Sinphar Pharmaceutical Co Ltd - Net Assets Trend (2002–2025)
This chart illustrates how Sinphar Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Sinphar Pharmaceutical Co Ltd asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Sinphar Pharmaceutical Co Ltd (2002–2025)
The table below shows the annual net assets of Sinphar Pharmaceutical Co Ltd from 2002 to 2025. For live valuation and market cap data, see market cap of Sinphar Pharmaceutical Co Ltd.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | NT$3.72 Billion ≈ $117.05 Million |
+4.77% |
| 2024-12-31 | NT$3.55 Billion ≈ $111.72 Million |
+4.36% |
| 2023-12-31 | NT$3.40 Billion ≈ $107.05 Million |
+5.63% |
| 2022-12-31 | NT$3.22 Billion ≈ $101.35 Million |
+4.54% |
| 2021-12-31 | NT$3.08 Billion ≈ $96.95 Million |
-2.12% |
| 2020-12-31 | NT$3.14 Billion ≈ $99.05 Million |
-1.84% |
| 2019-12-31 | NT$3.20 Billion ≈ $100.91 Million |
-6.43% |
| 2018-12-31 | NT$3.42 Billion ≈ $107.84 Million |
-5.62% |
| 2017-12-31 | NT$3.63 Billion ≈ $114.26 Million |
-4.11% |
| 2016-12-31 | NT$3.78 Billion ≈ $119.16 Million |
-4.50% |
| 2015-12-31 | NT$3.96 Billion ≈ $124.77 Million |
-2.90% |
| 2014-12-31 | NT$4.08 Billion ≈ $128.50 Million |
+16.73% |
| 2013-12-31 | NT$3.49 Billion ≈ $110.08 Million |
+29.86% |
| 2012-12-31 | NT$2.69 Billion ≈ $84.77 Million |
+1.13% |
| 2011-12-31 | NT$2.66 Billion ≈ $83.82 Million |
+23.13% |
| 2010-12-31 | NT$2.16 Billion ≈ $68.08 Million |
+3.22% |
| 2009-12-31 | NT$2.09 Billion ≈ $65.96 Million |
+17.95% |
| 2008-12-31 | NT$1.77 Billion ≈ $55.92 Million |
+4.41% |
| 2007-12-31 | NT$1.70 Billion ≈ $53.56 Million |
+2.17% |
| 2006-12-31 | NT$1.66 Billion ≈ $52.42 Million |
+1.18% |
| 2005-12-31 | NT$1.64 Billion ≈ $51.81 Million |
+24.92% |
| 2004-12-31 | NT$1.32 Billion ≈ $41.47 Million |
+39.60% |
| 2003-12-31 | NT$942.90 Million ≈ $29.71 Million |
+7.72% |
| 2002-12-31 | NT$875.36 Million ≈ $27.58 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Sinphar Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 330.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$364.27 Million | 10.58% |
| Common Stock | NT$1.90 Billion | 55.23% |
| Other Components | NT$1.18 Billion | 34.20% |
| Total Equity | NT$3.44 Billion | 100.00% |
Sinphar Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Sinphar Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ajinomoto Malaysia Bhd
KLSE:2658
|
$188.97 Million |
|
AMA Group Limited
F:KC7
|
$189.11 Million |
|
Haad Thip Public Company Limited
BK:HTC
|
$189.17 Million |
|
Samsung C and T 1P Pref
KO:02826K
|
$189.27 Million |
|
Hawesko Holding AG
XETRA:HAW
|
$188.69 Million |
|
OrganiGram Holdings Inc
TO:OGI
|
$188.68 Million |
|
Gaon Group Ltd
TA:GAGR
|
$188.63 Million |
|
Frauenthal Holding AG
VI:FKA
|
$188.60 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sinphar Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 3,263,201,000 to 3,443,873,000, a change of 180,672,000 (5.5%).
- Net income of 365,751,000 contributed positively to equity growth.
- Dividend payments of 181,140,000 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$365.75 Million | +10.62% |
| Dividends Paid | NT$181.14 Million | -5.26% |
| Other Changes | NT$-3.94 Million | -0.11% |
| Total Change | NT$- | 5.54% |
Book Value vs Market Value Analysis
This analysis compares Sinphar Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.69x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 3.81x to 1.69x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-12-31 | NT$8.27 | NT$31.50 | x |
| 2005-12-31 | NT$10.44 | NT$31.50 | x |
| 2006-12-31 | NT$10.43 | NT$31.50 | x |
| 2007-12-31 | NT$10.68 | NT$31.50 | x |
| 2008-12-31 | NT$11.16 | NT$31.50 | x |
| 2009-12-31 | NT$13.45 | NT$31.50 | x |
| 2010-12-31 | NT$13.85 | NT$31.50 | x |
| 2011-12-31 | NT$16.60 | NT$31.50 | x |
| 2012-12-31 | NT$15.08 | NT$31.50 | x |
| 2013-12-31 | NT$17.94 | NT$31.50 | x |
| 2014-12-31 | NT$19.70 | NT$31.50 | x |
| 2015-12-31 | NT$17.77 | NT$31.50 | x |
| 2016-12-31 | NT$18.43 | NT$31.50 | x |
| 2017-12-31 | NT$18.32 | NT$31.50 | x |
| 2018-12-31 | NT$17.44 | NT$31.50 | x |
| 2019-12-31 | NT$15.35 | NT$31.50 | x |
| 2020-12-31 | NT$15.15 | NT$31.50 | x |
| 2021-12-31 | NT$15.03 | NT$31.50 | x |
| 2022-12-31 | NT$16.15 | NT$31.50 | x |
| 2023-12-31 | NT$17.10 | NT$31.50 | x |
| 2024-12-31 | NT$17.98 | NT$31.50 | x |
| 2025-12-31 | NT$18.66 | NT$31.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sinphar Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.62%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 10.85%
- • Asset Turnover: 0.55x
- • Equity Multiplier: 1.79x
- Recent ROE (10.62%) is above the historical average (5.06%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | 7.09% | 6.77% | 0.55x | 1.89x | NT$-25.47 Million |
| 2003 | 7.52% | 6.38% | 0.54x | 2.19x | NT$-23.38 Million |
| 2004 | 10.24% | 8.65% | 0.60x | 1.97x | NT$2.85 Million |
| 2005 | 10.33% | 9.06% | 0.60x | 1.89x | NT$4.96 Million |
| 2006 | 2.92% | 2.68% | 0.59x | 1.85x | NT$-106.39 Million |
| 2007 | 5.24% | 4.57% | 0.56x | 2.06x | NT$-73.25 Million |
| 2008 | 2.87% | 2.55% | 0.50x | 2.23x | NT$-114.63 Million |
| 2009 | 6.72% | 7.23% | 0.51x | 1.84x | NT$-63.97 Million |
| 2010 | 5.47% | 6.09% | 0.49x | 1.83x | NT$-91.74 Million |
| 2011 | 2.92% | 3.92% | 0.40x | 1.87x | NT$-175.28 Million |
| 2012 | 4.92% | 5.96% | 0.46x | 1.79x | NT$-128.62 Million |
| 2013 | 10.00% | 11.66% | 0.45x | 1.90x | NT$-125.40K |
| 2014 | 4.94% | 6.18% | 0.41x | 1.96x | NT$-167.03 Million |
| 2015 | 0.43% | 0.64% | 0.34x | 1.98x | NT$-307.94 Million |
| 2016 | 0.54% | 0.78% | 0.34x | 2.01x | NT$-292.63 Million |
| 2017 | 1.19% | 1.72% | 0.35x | 1.97x | NT$-270.76 Million |
| 2018 | 0.30% | 0.40% | 0.38x | 2.01x | NT$-283.82 Million |
| 2019 | 0.50% | 0.58% | 0.40x | 2.13x | NT$-264.35 Million |
| 2020 | -1.04% | -1.19% | 0.39x | 2.23x | NT$-302.95 Million |
| 2021 | -1.40% | -1.57% | 0.39x | 2.29x | NT$-310.36 Million |
| 2022 | 7.67% | 7.86% | 0.46x | 2.11x | NT$-68.38 Million |
| 2023 | 12.11% | 12.66% | 0.47x | 2.02x | NT$65.34 Million |
| 2024 | 9.34% | 9.67% | 0.50x | 1.93x | NT$-21.62 Million |
| 2025 | 10.62% | 10.85% | 0.55x | 1.79x | NT$21.36 Million |
Industry Comparison
This section compares Sinphar Pharmaceutical Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,600,430,889
- Average return on equity (ROE) among peers: 3.21%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sinphar Pharmaceutical Co Ltd (1734) | NT$3.72 Billion | 7.09% | 0.66x | $188.76 Million |
| Apex Biotechnology Corp (1733) | $1.35 Billion | 29.84% | 0.15x | $89.90 Million |
| Panion & BF Biotech Inc (1760) | $2.01 Billion | 9.08% | 0.54x | $184.23 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $3.36 Billion | 1.58% | 0.42x | $68.46 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $996.24 Million | 6.00% | 0.56x | $99.61 Million |
| Level Biotechnology (3118) | $522.28 Million | 13.08% | 0.40x | $34.35 Million |
| GenMont Biotech Inc (3164) | $290.14 Million | -2.84% | 0.08x | $47.96 Million |
| Medigen Biotechnology (3176) | $3.54 Billion | -16.06% | 0.36x | $144.62 Million |
| Sagittarius Life Science (3205) | $965.47 Million | -11.83% | 0.10x | $119.60 Million |
| Genovate Biotechnology Co Ltd (4130) | $1.38 Billion | 0.03% | 0.10x | $98.37 Million |
About Sinphar Pharmaceutical Co Ltd
Sinphar Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the production, processing, selling, and trading of various medicines, Chinese medicines, medical cosmetic products and nutrients in Taiwan, Mainland China, Vietnam, Indonesia, and internationally. It operates through three segments: Pharmaceuticals, Healthy Food, and Others. The company offers pharmaceutical products, in… Read more